Whitehawk Therapeutics (NasdaqCM:AADI) FY Conference Transcript

Summary of Whitehawk Therapeutics FY Conference Call Company Overview - Company Name: Whitehawk Therapeutics (NasdaqCM:AADI) - Founded: 2025, initially launched with in-licensing of a 3 ADC portfolio from WuXi Biologics [2][3] - Current Status: Clinical stage company with two assets in the clinic and a third expected to enter clinical trials in Q3 2026 [3][4] Financial Position - Cash Position: $160 million as of Q3 2025, providing a runway to operate into 2028 [4] Product Pipeline ADC Portfolio 1. HWK-007: - Target: PTK7-ADC, focused on gynecological cancers [3][10] - Clinical Status: In the clinic, with initial phase I dose-escalation studies [10][11] - Potency: 3-10x greater than average Topo 1 inhibitor ADCs, with 5-25 times more stability [9][10] - Comparison: Shows improved efficacy over Pfizer's cofetuzumab pelidotin, with significant tumor regression at lower doses [15][17] 2. HWK-016: - Target: MUC16, focusing on ovarian and endometrial cancers [11][18] - Clinical Status: Currently recruiting patients for phase I dose-escalation trial [11][26] - Expression: 3-10 times more highly expressed in ovarian cancer compared to other ADC targets [18][20] - Innovation: Targets a portion of MUC16 that remains on the cell surface, avoiding issues with circulating biomarkers [22][24] 3. HWK-206: - Target: SEZ6, expected to file IND by mid-2026 and start clinical trials in Q3 2026 [11][27] - Competitive Edge: Designed to improve upon existing programs like ABBV-706, with enhanced targeting and internalization [27] Technology Differentiation - ADC Design: Focus on three components: 1. Targeting: High-affinity antibody selection and clinically validated targets [5][6] 2. Bioconjugation: Utilizes a paired carbon-bonded linker for improved stability and reduced payload loss [7][8] 3. Linker Payload: Smart delivery system that minimizes toxicity while maximizing tumor killing [8][9] Clinical Strategy - Focus: Targeting clinically validated but underdeveloped tumor targets to build best-in-class ADCs [27][28] - Patient Population: Selective focus on homogeneous patient populations for clinical trials to demonstrate efficacy and safety [25][26] Upcoming Milestones - Clinical Data Readouts: Anticipated in the first half of 2027 for both HWK-007 and HWK-016 [26][28] - Preclinical Data Release: Expected in spring 2026, showcasing profiles for each program [29] Conclusion - Whitehawk Therapeutics is positioned to leverage its innovative ADC technology and strong financial backing to advance its clinical programs, with a focus on differentiated therapeutic profiles and robust clinical data expected in the near future [28]